Closing the Performance Gap in Managing Major Depressive Disorder and Comorbid Anxiety
neuroscienceCME Webcast
Premiere Date: Monday, July 16, 2007This activity offers CE credit for:
Physicians (ACCME/AMA PRA Category 1)All other clinicians will receive a CME Attendance Certificate.
Credit Expiration Date:
Wednesday, July 16, 2008
 | Siegfried Kasper, MD Professor of Psychiatry Chairman, Department of General Psychiatry Medical University of Vienna Vienna, Austria |
 | Pedro L. Delgado, MD Dielmann Distinguished Chair in Psychiatry Professor and Chairman of the Department of Psychiatry Associate Dean for Faculty Development and Professionalism The University of Texas Health Science Center at San Antonio San Antonio, TX |
 | Julio Licinio, MD Professor and Chairman Department of Psychiatry and Behavioral Sciences Leonard M. Miller School of Medicine University of Miami Miami, FL |
Major depressive disorder (MDD) is now the fourth-leading cause of the global disease burden and the leading
cause of disability worldwide; WHO expects that depression will be the second leading cause of disability after heart
disease by 2020.(1,2) Cost-effective interventions are available, but do not often reach those who need them because
of a number of overwhelming challenges in low-resource settings - including lack of facilities and trained mental
health personnel, questions about effective population-based screening, and the general stigma surrounding mental
disorders. Generalized anxiety disorder (GAD) is a chronic, disabling disorder associated with substantial personal,
societal, and economic costs.(3) Co-existing GAD in depressed patients may worsen the outcome by increasing the
rates of suicide, worsening overall symptoms, conferring a poorer response to treatment, increasing the number of
medically unexplained symptoms, and increasing functional disability. The comorbidity of GAD with major depressive
episode (MDE) has been of special interest because of the high level of comorbidity and the status of MDE as one
of the most burdensome disorders worldwide.(4) In this live activity, the faculty experts will review the importance
of early recognition of MDD and comorbid anxiety and focus on innovative strategies to manage these challenging
comorbidities in patients from both developed and developing countries.
- Hyman S, et al. Mental Disorders. In: Disease Control Priorities in Developing Countries, 2nd ed., ed. Dean T. Jamison et al. New York: Oxford University Press, 2006.
- The WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization world mental health surveys. JAMA 2004;291:2581-2590.
- Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:616-627.
- World Health Organization (WHO), Gender and Women’s Mental Health (1997), accessed online at www.who.int. Accessed 10/23/2006.
Credit Requirements
Successful completion of this CME activity includes participating in the recorded activity, reviewing the course
materials, and following the appropriate set of instructions below by July 16, 2008:
Option A:
To complete your credit request form, activity evaluation, and post-test online (80% pass rate required), and print your
certificate immediately, please visit www.neuroscienceCME.com and click on the Testing/Certification link under the
Resources tab (requires free account activation).
Option B:
Complete the credit request form and activity evaluation located in the main menu under "Course Guide, Post-Test
and CME Credit Forms." Successfully complete the post-test (80%) and record your responses on the credit request
form.
Submit completed forms via FAX to 240.243.1033 or mail to:
CME Outfitters, LLC
2400 Research Boulevard, Suite 425
Rockville, MD 20850
Attention: CE Forms Processor
Participants will receive a certificate within 4-6 weeks following receipt of the credit request form and activity
evaluation form.
To provide evidence-based educational information regarding the global prevalence, recognition, and management of depression with comorbid anxiety.
At the end of this CE activity, participants should be able to:
- Identify three patient barriers that contribute to the performance gap noted by the World Health Organization.
- Provide clinicians with tools and strategies to improve the delivery of cost-effective interventions for patients with comorbid anxiety and depression.
- Implement innovative and novel teaching approaches to improve the global performance gap in the diagnosis and management of depression and comorbid anxiety.
Physicians, especially psychiatrists, and other healthcare professionals with an interest in mental health.
CME Outfitters, LLC, gratefully acknowledges an educational grant from Wyeth Pharmaceuticals in support of this CE activity.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing
medical education for physicians.
CME Outfitters, LLC, designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.
Disclosure Declaration
All faculty participating in CME Outfitters continuing education activities are required to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME's Standards for Commercial Support, and other accrediting and regulatory bodies. Full disclosure of faculty relationships will be made on this website and within the activity course materials prior to the premiere date of this activity.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMV-009-071607-07
